Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Short-Term Debt issuances (2019 - 2022)

United Therapeutics' Short-Term Debt issuances history spans 3 years, with the latest figure at $800.0 million for Q1 2022.

  • For Q1 2022, Short-Term Debt issuances changed N/A year-over-year to $800.0 million; the TTM value through Dec 2022 reached $800.0 million, changed N/A, while the annual FY2025 figure was $200.0 million, N/A changed from the prior year.
  • Short-Term Debt issuances for Q1 2022 was $800.0 million at United Therapeutics, roughly flat from $800.0 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $800.0 million in Q1 2019 and bottomed at $800.0 million in Q1 2019.